Recognizing the 2019 Global Genes RARE Champion of Hope Award winners.
Frederick W. Miller, M.D., Ph.D., retires as an IMACS Coordinator and Deputy Chief of the Clinical Research Branch of NIEHS, NIH.
The 2nd Global Conference on Myositis was held May 5-8, 2017 in Potomac, Maryland.
The First International Conference on Myositis was held in Stockholm Sweden from May 8 - 11, 2015 at the Radisson Blu Royal Park Hotel.
Investigators plan to develop criteria for clinical improvement and responses for patients with adult and juvenile dermatomyositis and polymyositis.
The Cure JM Foundation won a $250,000 grant from Pepsi in the Pepsi Refresh national contest in August 2010.
The Myositis Association (TMA) is pleased to announce MYOVISION, a myositis patient registry designed to capture environmental exposures and other potential triggers of myositis. Utilizing funding from the Centers for Disease Control and Prevention, TMA will collect from adults and children with myositis information about their disease.
A short breakfast meeting was planned for Monday, October 27, 2008 from 6:15 to 8:30 a.m. in San Francisco, CA. This meeting was held in conjunction with the American College of Rheumatology JDM Working Group.
The International Myositis Classification Criteria Project, which is a multi-disciplinary international effort to develop new classification criteria for adult and juvenile myositis, was open for data collection.
The database for this repository has been completed and the repository is open for submission of trials and natural history studies.
A short breakfast meeting was planned for Saturday, November 10, 2007 at 6:45 - 9:00 a.m. in Boston, MA. This meeting was held in conjunction with the ACR JDM Working Group.
A short breakfast meeting was planned for Tuesday, November 14, 2006 at 7:00 - 9:00 a.m. in Washington, DC. This meeting was held in conjunction with the ACR JDM Working Group.
A number of classification criteria for idiopathic inflammatory myopathies and the major subgroups have been proposed over the last three decades. Unfortunately, most of these have been based on clinical impressions rather than data analyses, and none have been fully tested for sensitivity or specificity using appropriately powered studies against all the appropriate disease confounders.
A short breakfast meeting was planned for Sunday, November 13, 2005 at 7:00 -9:00 a.m. prior to the American College of Rheumatology meeting in San Diego, California. This meeting was held in conjunction with the ACR JDM Working Group.
Proposals were being sought for potential investigative opportunities using the planned data and sample collection from the RIM Study.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health sponsored an international multi-center trial to be conducted in both adult and juvenile myositis.
IMACS developed a Clinical Trial/Study Outcomes Data Repository which captures IMACS core activity, damage and patient-reported outcome measures and related trial/study information.
As the result of a series of international consensus workshops, IMACS partially validated Preliminary Definitions of Improvement for Adult and Juvenile Myositis.